1. Inicio
  2. Publicaciones
  3. Empagliflozin in Heart Failure with a Preserved Ejection Fraction

Empagliflozin in Heart Failure with a Preserved Ejection Fraction

Fecha de publicación: Fecha Ahead of Print:

Autores Icesi

Participantes ajenos a Icesi

  • Anker, SD
  • Butler, J
  • Filippatos, G
  • Ferreira, JP
  • Bocchi, E
  • Bohm, M
  • Brunner-La Rocca, HP
  • Choi, DJ
  • Chopra, V
  • Chuquiure-Valenzuela, E
  • Giannetti, N
  • Janssens, S
  • Januzzi, JL
  • Gonzalez-Juanatey, JR
  • Merkely, B
  • Nicholls, SJ
  • Perrone, SV
  • Pina, IL
  • Ponikowski, P
  • Senni, M
  • Sim, D
  • Spinar, J
  • Squire, I
  • Taddei, S
  • Tsutsui, H
  • Verma, S
  • Vinereanu, D
  • Zhang, J
  • Carson, P
  • Lam, CSP
  • Marx, N
  • Zeller, C
  • Sattar, N
  • Jamal, W
  • Schnaidt, S
  • Schnee, JM
  • Brueckmann, M
  • Pocock, SJ
  • Zannad, F
  • Packer, M
  • EMPEROR Preserved Trial

Unidades de Investigación

Resumen

BACKGROUND Sodium-glucose cotransporter 2 inhibitors reduce the risk of hospitalization for heart failure in patients with heart failure and a reduced ejection fraction, but their effects in patients with heart failure and a preserved ejection fraction are uncertain. METHODS In this double-blind trial, we randomly assigned 5988 patients with class II-IV heart failure and an ejection fraction of more than 40% to receive empagliflozin (10 mg once daily) or placebo, in addition to usual therapy. The primary outcome was a composite of cardiovascular death or hospitalization for heart failure. RESULTS Over a median of 26.2 months, a primary outcome event occurred in 415 of 2997 patients (13.8%) in the empagliflozin group and in 511 of 2991 patients (17.1%) in the placebo group (hazard ratio, 0.79; 95% confidence interval [CI], 0.69 to 0.90; P<0.001). This effect was mainly related to a lower risk of hospitalization for heart failure in the empagliflozin group. The effects of empagliflozin appeared consistent in patients with or without diabetes. The total number of hospitalizations for heart failure was lower in the empagliflozin group than in the placebo group (407 with empagliflozin and 541 with placebo; hazard ratio, 0.73; 95% CI, 0.61 to 0.88; P<0.001). Uncomplicated genital and urinary tract infections and hypotension were reported more frequently with empagliflozin. CONCLUSIONS Empagliflozin reduced the combined risk of cardiovascular death or hospitalization for heart failure in patients with heart failure and a preserved ejection fraction, regardless of the presence or absence of diabetes.

Datos de la publicación

ISSN/ISSNe:
0028-4793, 1533-4406

NEW ENGLAND JOURNAL OF MEDICINE  Massachusetts Medical Society

Tipo:
Article
Páginas:
1451-1461
PubMed:
34449189
Enlace a otro recurso:
www.scopus.com
Factor de Impacto:
24.907 SCImago ℠
Cuartil:
Q1 SCImago ℠

Citas Recibidas en Web of Science: 531

Citas Recibidas en Scopus: 3,495

Documentos

  • No hay documentos

Métricas

Filiaciones mostrar / ocultar

Keywords

  • empagliflozin; placebo; aged; Article; cardiovascular mortality; clinical outcome; confidence interval; controlled study; double blind procedure; drug effect; drug withdrawal; female; genital tract infection; hazard ratio; heart ejection fraction; heart failure; heart failure with preserved ejection fraction; hospitalization; human; hypotension; major clinical study; male; randomized controlled trial; urinary tract infection

Campos de Estudio

Cita

Compartir